The 4^th Glioblastoma Drug Development Summit was the premier event for pharmaceutical and biotech researchers to discuss advances, challenges, and new solutions in the field of GBM therapy.

This 3-day summit featured leading companies and organizations including AstraZeneca, Bristol-Myers Squibb, Kazia Therapeutics and Oncorus, who will address significant topics such as GBM Agile, combinational therapies, funding challenges and next-generation therapeutic modalities.

This industry focused summit heard from the leaders of the GBM field,

• Optimizing clinical trial design, with deep dives into endpoints, pre-clinical model selection and updates on RANO and GBM AGILE, designed helping you gain clarity with approaching the clinic
• Evaluating combinational approaches that enhance existing treatments, with a spotlight on DDR inhibition and radiotherapy and how moving away from monotherapy can maximize efficacy
• Navigating novel therapeutic modalities in treating glioblastomas and understanding how people are approaching CAR-T, CAR-NK, RNA Vaccines and many more new approaches to tackling this devastating disease

With such a short life expectancy and lack of treatment options for patients, it’s time to give this devastating disease the urgent attention it needs.